<DOC>
	<DOCNO>NCT00520975</DOCNO>
	<brief_summary>This randomized phase III trial study first-line chemotherapy trastuzumab compare well work give without bevacizumab treat patient breast cancer overexpresses human epidermal growth factor receptor 2 ( HER-2/NEU ) spread area body . Drugs use chemotherapy , paclitaxel carboplatin , work different way stop growth tumor cell , either kill cell , stop dividing , stop spread . Monoclonal antibody , trastuzumab bevacizumab , may interfere ability tumor cell grow spread . Bevacizumab may also stop growth breast cancer block growth new blood vessel necessary tumor growth . It yet know whether give first-line chemotherapy together trastuzumab effective without bevacizumab treat patient metastatic breast cancer overexpresses HER-2/NEU .</brief_summary>
	<brief_title>Bevacizumab Treating Patients With Metastatic Breast Cancer That Overexpresses HER-2/NEU</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . Evaluate efficacy addition bevacizumab patient eligible first-line trastuzumab chemotherapy HER-2/NEU overexpressing metastatic breast cancer , assess progression-free survival ( PFS ) initiation combination therapy . SECONDARY OBJECTIVES : I . Evaluate response rate ( RR ) patient measurable disease ( Response Evaluation Criteria Solid Tumors [ RECIST ] ) , applicable . II . Evaluate overall survival ( OS ) . III . Evaluate proportion progression-free 6 month . IV . Compare toxicity chemotherapy/trastuzumab chemotherapy/ trastuzumab combination bevacizumab . V. Evaluate leave ventricular ejection fraction ( LVEF ) decline clinical congestive heart failure ( CHF ) . EXPLORATORY OBJECTIVES : I . Compare breast cancer symptom treatment relate symptom patient receive chemotherapy trastuzumab without bevacizumab . II . Evaluate whether PFS correlate vascular endothelial growth factor ( VEGF ) level breast tumor tissue . III . Analysis circulate tumor cell circulate endothelial cell ( CEC ) . 1 . Serially enumerate circulate tumor cell ( CTC ) CEC patient study determine whether : number CTC CEC decrease respond patient ; extent CTC CEC decrease great experimental arm , Arm B versus control arm , Arm A ; enumeration CTC CEC respond patient correlate progression free survival ( PFS ) . 2 . Perform exploratory analysis phosphorylation status v-akt murine thymoma viral oncogene homolog ( akt ) -2 circulate tumor cell . 3 . Perform exploratory analysis reverse transcriptase ( RT ) -polymerase chain reaction ( PCR ) CTC messenger ribonucleic acid ( mRNA ) determine whether change expression select downstream target bevacizumab therapy serve pharmacodynamic surrogate marker bevacizumab target modulation . OUTLINE : Patients randomize 1 2 treatment arm . ARM A : INDUCTION THERAPY : Patients receive trastuzumab intravenously ( IV ) 30-90 minute day 1 , 8 , 15 , 22 paclitaxel IV 60 minute without carboplatin IV 60 minute day 1 , 8 , 15 . Patients also receive placebo IV 30-90 minute day 1 15 . Treatment repeat every 4 week 6 course absence disease progression unacceptable toxicity . MAINTENANCE THERAPY : Beginning 1 week last dose induction trastuzumab , patient receive trastuzumab IV 30-90 minute placebo IV 30-90 minute day 1 . Treatment repeat every 3 week absence disease progression unacceptable toxicity . ARM B : INDUCTION THERAPY : Patients receive trastuzumab paclitaxel without carboplatin Arm A . Patients also receive bevacizumab IV 30-90 minute day 1 15 . Treatment repeat every 4 week 6 course absence disease progression unacceptable toxicity . MAINTENANCE THERAPY : Beginning 1 week last dose induction trastuzumab , patient receive trastuzumab IV 30-90 minute bevacizumab IV 30-90 minute day 1 . Treatment repeat every 3 week absence disease progression unacceptable toxicity . After completion study treatment , patient follow 10 year . PROJECTED ACCRUAL : 489 patient</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Histologically confirm breast cancer overexpresses HER2/NEU evidence metastatic disease and/or chest wall recurrence prior randomization HER2/NEU overexpression define 3+ HER2 positivity measure immunohistochemistry OR HER2 gene amplification measure fluorescent situ hybridization ( FISH , e.g . Vysis ) , per American Society Clinical Oncology guideline NOTE : representative diagnostic tissue must submit central diagnostic review confirmation HER2/NEU overexpression within two week follow patient randomization Evaluable ( measurable nonmeasurable ) disease allow confirm within 4 week prior randomization Prior endocrine treatment adjuvant metastatic setting allow , provide last dose give &gt; = 2 week prior randomization Radiation therapy allow provide last dose give &gt; = 3 week prior randomization Adjuvant trastuzumab therapy breast cancer allow provide last dose give &gt; = 12 month prior diagnosis recurrence Adjuvant neoadjuvant taxane therapy breast cancer allow provide last dose give &gt; = 12 month prior diagnosis recurrence Adjuvant neoadjuvant therapy lapatinib allow provide last dose give &gt; = 4 week prior diagnosis recurrence Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 Absolute neutrophil count &gt; = 1,000/mm^3 Platelet count &gt; = 100,000/mm^3 Total bilirubin = &lt; 1.5 mg/dL Aspartate aminotransferase ( AST ) = &lt; 2 time upper limit normal ( ULN ) ( = &lt; 5 time normal patient know liver involvement ) Serum creatinine = &lt; 1.5 mg/dL Urine protein : creatinine ratio = &lt; 0.5 OR 24hour urine protein &lt; 1000 mg International normalize ratio ( INR ) = &lt; 1.5 X ULN Partial thromboplastin time ( PTT ) = &lt; 1.5 X ULN Multi gate acquisition scan ( MUGA ) scan echocardiogram ( ECHO ) within 6 week prior randomization leave ventricular ejection fraction ( LVEF ) institutional low limit normal Patients must able understand provide sign date write informed consent Major surgical procedure within 4 week prior randomization allow ( except nonoperative biopsy , would consider major surgery ) ; treatment begin seven ( 7 ) day placement vascular access device Women must pregnant breastfeeding ; female childbearing potential must blood urine test within 2 week prior randomization rule pregnancy ; woman childbearing potential sexually active male must use accepted effective method contraception Patients fulldose anticoagulant ( e.g. , warfarin ) PT/INR &gt; 1.5 may eligible provide follow criterion meet : The patient inrange INR ( usually 2 3 ) stable dose oral anticoagulant stable dose low molecular weight heparin The patient active bleed pathological condition carry high risk bleeding ( e.g. , tumor involve major vessel know varix ) Patients concurrent active malignancy except carcinoma situ cervix nonmelanoma skin cancer ( unless diseasefree least 5 year study entry ) allow Prior chemotherapy , trastuzumab , bevacizumab metastatic breast cancer Patients cumulative dose doxorubicin great 360 mg/m^2 epirubicin great 640 mg/m^2 adjuvant neoadjuvant setting time Patients grade 24 neuropathy Patients history radiologic evidence central nervous system ( CNS ) disease Patients current nonhealing wound fracture Patients hypersensitivity paclitaxel drug use vehicle Cremophor , Chinese hamster ovary cell product recombinant human antibody Patients serious medical psychiatric illness would prevent ability safely participate provide informed consent Patients use follow drug know inhibit platelet function eligible : dipyridamole ( Persantine ) , ticlopidine ( Ticlid ) , clopidogrel ( Plavix ) cilostazol ( Pletal ) Clinically significant cardiovascular disease , include : History cerebrovascular ( CVA ) within 6 month Uncontrolled hypertension Myocardial infarction unstable angina within 6 month New York Heart Association class II great congestive heart failure , serious cardiac arrhythmia require medication , unstable angina pectoris Clinically significant peripheral vascular disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Trastuzumab</keyword>
	<keyword>Bevacizumab</keyword>
	<keyword>Metastatic Breast Cancer</keyword>
	<keyword>HER2/NEU</keyword>
</DOC>